![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jubilant HollisterStier LLC, has signed a contract with Eli Lilly and Company (Lilly), for contract manufacturing of Bamlanivimab, that has been granted Emergency Use Authorization by the FDA for emergency use as a treatment of COVID 19.
Lead Product(s): Bamlanivimab
Therapeutic Area: Infections and Infectious Diseases Product Name: LY-CoV555
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021